{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.04","value":"64.09"},{"groupId":"OG001","spread":"20.74","value":"66.76"}]}],"title":"Baseline (n=164, 161)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.42","value":"69.19"},{"groupId":"OG001","spread":"20.30","value":"66.33"}]}],"title":"C2D1 (n=153, 131)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.97","value":"73.13"},{"groupId":"OG001","spread":"20.80","value":"65.84"}]}],"title":"C3D1 (n=153, 105)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.25","value":"73.78"},{"groupId":"OG001","spread":"18.14","value":"69.13"}]}],"title":"C4D1 (n=135, 90)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.99","value":"75.27"},{"groupId":"OG001","spread":"23.19","value":"68.12"}]}],"title":"C5D1 (n=122, 74)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.67","value":"75.79"},{"groupId":"OG001","spread":"22.46","value":"69.71"}]}],"title":"C6D1 (n=120, 70)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.34","value":"77.02"},{"groupId":"OG001","spread":"24.31","value":"70.63"}]}],"title":"C7D1 (n=115, 52)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.09","value":"74.72"},{"groupId":"OG001","spread":"23.54","value":"72.30"}]}],"title":"C8D1 (n=110, 43)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.32","value":"74.45"},{"groupId":"OG001","spread":"25.85","value":"72.27"}]}],"title":"C9D1 (n=101, 37)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.18","value":"75.49"},{"groupId":"OG001","spread":"24.88","value":"74.27"}]}],"title":"C10D1 (n=94, 33)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.00","value":"76.32"},{"groupId":"OG001","spread":"20.31","value":"77.24"}]}],"title":"C11D1 (n=84, 25)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.63","value":"76.95"},{"groupId":"OG001","spread":"22.60","value":"74.83"}]}],"title":"C12D1 (n=77, 23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.50","value":"76.38"},{"groupId":"OG001","spread":"23.54","value":"73.00"}]}],"title":"C13D1 (n=73, 21)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.54","value":"78.77"},{"groupId":"OG001","spread":"22.56","value":"74.11"}]}],"title":"C14D1 (n=66, 19)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.78","value":"77.71"},{"groupId":"OG001","spread":"19.52","value":"77.44"}]}],"title":"C15D1 (n=62, 16)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.21","value":"75.32"},{"groupId":"OG001","spread":"13.28","value":"79.00"}]}],"title":"C16D1 (n=53, 12)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.68","value":"75.09"},{"groupId":"OG001","spread":"15.98","value":"81.73"}]}],"title":"C17D1 (n=47, 11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.63","value":"75.87"},{"groupId":"OG001","spread":"16.25","value":"78.91"}]}],"title":"C18D1 (n=45, 11)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.39","value":"76.85"},{"groupId":"OG001","spread":"14.04","value":"78.00"}]}],"title":"C19D1 (n=40, 9)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.81","value":"72.66"},{"groupId":"OG001","spread":"17.65","value":"76.75"}]}],"title":"C20D1 (n=35, 8)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.19","value":"74.13"},{"groupId":"OG001","spread":"19.41","value":"73.63"}]}],"title":"C21D1 (n=30, 8)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.54","value":"77.54"},{"groupId":"OG001","spread":"19.79","value":"72.21"}]}],"title":"C22D1 (n=24, 7)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.75","value":"75.48"},{"groupId":"OG001","spread":"16.35","value":"54.00"}]}],"title":"C23D1 (n=23, 4)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.15","value":"71.40"},{"groupId":"OG001","spread":"20.30","value":"62.00"}]}],"title":"C24D1 (n=20, 3)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.97","value":"75.61"},{"groupId":"OG001","spread":"22.59","value":"63.67"}]}],"title":"C25D1 (n=18, 3)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.71","value":"72.14"},{"groupId":"OG001","spread":"17.52","value":"63.00"}]}],"title":"C26D1 (n=14, 3)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.96","value":"66.57"},{"groupId":"OG001","spread":"14.14","value":"50.00"}]}],"title":"C27D1 (n=14, 2)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.72","value":"72.36"},{"groupId":"OG001","spread":"21.21","value":"55.00"}]}],"title":"C28D1 (n=11, 2)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.28","value":"71.38"},{"groupId":"OG001","spread":"14.14","value":"45.00"}]}],"title":"C29D1 (n=8, 2)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.00","value":"69.50"},{"comment":"Standard deviation was not estimable since only one participant was evaluable","groupId":"OG001","spread":"NA","value":"40.00"}]}],"title":"C30D1 (n=8, 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.76","value":"68.57"},{"comment":"Data was not analyzed as no participants were evaluable","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"C31D1 (n=7, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.41","value":"65.83"},{"comment":"Data was not analyzed as no participants were evaluable","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"C32D1 (n=6, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.34","value":"67.50"},{"comment":"Data was not analyzed as no participants were evaluable","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"C33D1 (n=6, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.80","value":"68.00"},{"comment":"Data was not analyzed as no participants were evaluable","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"C34D1 (n=5, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.84","value":"72.25"},{"comment":"Data was not analyzed as no participants were evaluable","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"C35D1 (n=4, 0)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not estimable since only one participant was evaluable","groupId":"OG000","spread":"NA","value":"90.00"},{"comment":"Data was not analyzed as no participants were evaluable","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"C36D1 (n=1, 0)"},{"categories":[{"measurements":[{"comment":"Standard deviation was not estimable since only one participant was evaluable","groupId":"OG000","spread":"NA","value":"85.00"},{"comment":"Data was not analyzed as no participants were evaluable","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"C37D1 (n=1, 0)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.25","value":"68.33"},{"groupId":"OG001","spread":"23.71","value":"58.34"}]}],"title":"EOT (n=49, 90)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"161"}],"units":"Participants"}],"description":"EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.","dispersionType":"Standard Deviation","groups":[{"description":"Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG000","title":"Crizotinib"},{"description":"Pemetrexed 500 mg/m\\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEAN","populationDescription":"FAS included all participants who were randomized to study treatment. Here \"N\" (number of participants analyzed) signifies participants who were evaluable for this measure and \"n\" signifies participants who were evaluable for specified time points for each arm group, respectively.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of each cycle until disease progression, end of treatment (up to 112 weeks)","title":"European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)","type":"SECONDARY","unitOfMeasure":"units on a scale"}